Skip to main content
EVH logo

EVH · Evolent Health, Inc. · Documents

Track EVH — free
$3.90 +0.47 (+13.70%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$441.11M
Shares
113.11M
Volume · Nov 20 4.42M Avg daily vol (3M) 2.16M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $1.88B down 26.6% 10-K filed Feb 25, 2026 Quarterly report FY2026 Q3 Revenue $725.37M up 51.3% 10-Q filed Nov 5, 2026 Latest results Revenue grew as 2026 EBITDA guidance increased 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 5
Earnings call
Adjusted EBITDA guidance raised to $130 million to $135 million

Evolent reported $725 million of quarterly revenue and $34.3 million of adjusted EBITDA, up approximately 22% sequentially, while raising full-year adjusted EBITDA guidance to $130 million to $135 million and reiterating revenue guidance of $2.6 billion to $2.7 billion.

2 source passages
Total revenue was $725 million, up approximately 11% versus the second quarter. Adjusted EBITDA was $34.3 million, up approximately 22% sequentially. We are reiterating revenue guidance of $2.6 billion to $2.7 billion and raising our adjusted EBITDA guidance to $130 million to $135 million from $120 million to $135 million previously. Open the document at this passage
Nov 5
Current report 8-K
Revenue grew as 2026 EBITDA guidance increased

Evolent Health reported September 30, 2026 quarter revenue of 725,367 thousand dollars and adjusted EBITDA of 34,257 thousand dollars. It raised 2026 adjusted EBITDA guidance to $130.0 million to $135.0 million and reiterated $2.6 billion to $2.7 billion revenue guidance.

Financial results
4 source passages
Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2026. Revenue | 725,367 Adjusted EBITDA | 34,257 Incorporating its year-to-date performance, the Company is reiterating its 2026 revenue guidance range to $2.6 billion to $2.7 billion and raising its Adjusted EBITDA range to $130.0 million to $135.0 million. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 51.3% despite wider operating loss

Evolent Health reported revenue of $725.4 million for the three months ended September 30, 2026, up 51.3%, compared to 2025. Nine-month revenue rose 33.2% to $1.9 billion, while operating losses widened in both periods.

Revenue $725.37M ▲ 51.3% Net loss $23.57M Diluted EPS -$0.21
Read from the MD&A section
4 source passages
Total revenue increased by $245.8 million, or 51.3%, to $725.4 million for the three months ended September 30, 2026, as compared to 2025. Total revenue increased $466.6 million, or 33.2%, to $1.9 billion for the nine months ended September 30, 2026, compared to the same period in 2025. Operating income (loss) | (6,188) | 886 | (7,074) | (798.4)% | (26,348) | (1,907) | (24,441) | (1,281.6) % The following table represents Evolent’s revenue disaggregated by line of business (in thousands): Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $652.52M ▲ 46.9% Net loss $28.36M Diluted EPS -$0.25
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $496.25M ▲ 2.6% Net loss $26.63M Diluted EPS -$0.24
Apr 24
Proxy statement DEF 14A Meeting Jun 4, 2026
Proxy statement AI summary on its way
Feb 25
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $1.88B ▼ 26.6% Net loss $534.51M Diluted EPS -$5.07
2025
Feb 21
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $2.55B ▲ 30.1% Net loss $61.62M Diluted EPS -$0.81
2024
Showing 1–50 of 174 documents
Key facts CIK 1628908 CUSIP 30050B101 13F (30d) 212 filings 189 filers Visit website Investor relations